ResMed revenue and financials

RMD · NYSE · USD

$220.69−0.97%−$2.17

Close · October 6, 2026

In the fiscal year ended June 2026, ResMed reported revenue of $5.65B (+9.85% year over year). Net income was $1.52B, a net margin of 26.9%.

Annual revenue · 2026: $5.65B
  1. $2.07B2017
  2. $2.34B2018
  3. $2.61B2019
  4. $2.96B2020
  5. $3.2B2021
  6. $3.58B2022
  7. $4.22B2023
  8. $4.69B2024
  9. $5.15B2025
  10. $5.65B2026

Fiscal year ending in June. Sources and method on the page Methodology and sources.

At a glance

Revenue growth
+9.85%
FY to Jun 2026 vs FY to Jun 2025
Net income growth
+8.75%
FY to Jun 2026 vs FY to Jun 2025
Net margin
26.9%
FY to Jun 2025: 27.2%

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

ItemQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Total assets8,9668,7848,5038,3088,1747,5677,1417,2226,8726,8156,9056,741
Current assets4,3254,0643,8193,6263,5063,2082,8362,6412,3582,3512,3782,305
Cash and equivalents1,4691,6611,4171,3841,209933522426238238210209
Short-term investments—————————21.57.611.8
Receivables1,0851,0461,047958991991960811875817764726
Inventory9739379459729769299861,0649941,0271,1301,137
Net property, plant and equipment735729730726718688671717699687705657
Goodwill2,9103,0433,0443,0443,0472,8492,8052,8862,8422,8362,8622,812
Other intangible assets453425430447465430438479486501528563
Long-term investments157158144142140134132213139142141132
Current liabilities1,3951,3511,2481,2561,019941852904911773764771
Accounts payable309273250267278223220249238177202177
Long-term debt3994044044096586636636686979971,2171,352
Total debt826843848846852———————
Total liabilities2,3812,2922,1822,1872,2072,0211,8882,0272,0082,1852,4232,490
Total equity (incl. minority)6,5856,4926,3216,1215,9685,5465,2535,1954,8644,6304,4824,250
Retained earnings7,2556,9596,6476,3426,0815,7795,4925,2254,9924,7704,5404,402